FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending May 2009
 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --

 

 

 

 



BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an 
ris
.

Date:
 
11 May 2009

Name of 
applicant
:
GlaxoSmithKline plc
Name of scheme:
GlaxoSmithKline Share Option Plan - Ordinary Shares
Period of return:
From:
1 November 2008
To:
30 April 2009
Balance of unallotted securities under scheme(s) from previous return:
5,997,825
Plus:  
The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less:  
Number of 
securities
 issued/allotted under scheme(s) during period (see LR3.5.7G):
702,118
Equals:  
Balance under scheme(s) not yet issued/allotted at end of period:
5,295,707



Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000





 
 


BLOCK LISTING SIX MONTHLY RETURN

Information provided on this 
form
 must be typed or printed electronically 
and
 provided to an 
ris
.

Date:
 
11 May 2009

Name of 
applicant
:
GlaxoSmithKline plc
Name of scheme:
GlaxoSmithKline Share Option Plan - ADS
Period of return:
From:
1 November 2008
To:
30 April 2009
Balance of unallotted securities under scheme(s) from previous return:
6,397,824
Plus:  
The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less:  
Number of 
securities
 issued/allotted under scheme(s) during period (see LR3.5.7G):
8,400
Equals:  
Balance under scheme(s) not yet issued/allotted at end of period:
6,389,424



Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000






 
 


BLOCK LISTING SIX MONTHLY RETURN

Information provided on this 
form
 must be typed or printed electronically 
and
 provided to an 
ris
.

Date:
 
11 May 2009

Name of 
applicant
:
GlaxoSmithKline plc
Name of scheme:
Glaxo Wellcome 
UK
 Share Option Scheme
Period of return:
From:
1 November 2008
To:
30 April 2009
Balance of unallotted securities under scheme(s) from previous return:
5,119,750
Plus:  
The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less:  
Number of 
securities
 issued/allotted under scheme(s) during period (see LR3.5.7G):
0
Equals:  
Balance under scheme(s) not yet issued/allotted at end of period:
5,119,750



Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000






 
 


BLOCK LISTING SIX MONTHLY RETURN

Information provided on this 
form
 must be typed or printed electronically 
and
 provided to an 
ris
.

Date:
 
11 May 2009

Name of 
applicant
:
GlaxoSmithKline plc
Name of scheme:
Glaxo Wellcome International Share Option Scheme
Period of return:
From:
1 November 2008
To:
30 April 2009
Balance of unallotted securities under scheme(s) from previous return:
13,267,156
Plus:  
The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less:  
Number of 
securities
 issued/allotted under scheme(s) during period (see LR3.5.7G):
0
Equals:  
Balance under scheme(s) not yet issued/allotted at end of period:
13,267,156



Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000






 
 



BLOCK LISTING SIX MONTHLY RETURN

Information provided on this 
form
 must be typed or printed electronically 
and
 provided to an 
ris
.

Date:
 
11 May 2009

Name of 
applicant
:
GlaxoSmithKline plc
Name of scheme:
Glaxo Wellcome 1999 Share Option Plan
Period of return:
From:
1 November 2008
To:
30 April 2009
Balance of unallotted securities under scheme(s) from previous return:
1,040,000
Plus:  
The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less:  
Number of 
securities
 issued/allotted under scheme(s) during period (see LR3.5.7G):
0
Equals:  
Balance under scheme(s) not yet issued/allotted at end of period:
1,040,000



Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000






 
 


BLOCK LISTING SIX MONTHLY RETURN

Information provided on this 
form
 must be typed or printed electronically 
and
 provided to an 
ris
.

Date:
 
11 May 2009

Name of 
applicant
:
GlaxoSmithKline plc
Name of scheme:
SmithKline Beecham 1989 Executive Share Option Plan - Approved - Ordinary Shares
Period of return:
From:
1 November 2008
To:
30 April 2009
Balance of unallotted securities under scheme(s) from previous return:
163,606
Plus:  
The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less:  
Number of 
securities
 issued/allotted under scheme(s) during period (see LR3.5.7G):
0
Equals:  
Balance under scheme(s) not yet issued/allotted at end of period:
163,606



Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000






 
 


BLOCK LISTING SIX MONTHLY RETURN

Information provided on this 
form
 must be typed or printed electronically 
and
 provided to an 
ris
.

Date:
 
11 May 2009

Name of 
applicant
:
GlaxoSmithKline plc
Name of scheme:
SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - ADS
Period of return:
From:
1 November 2008
To:
30 April 2009
Balance of unallotted securities under scheme(s) from previous return:
275,420
Plus:  
The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less:  
Number of 
securities
 issued/allotted under scheme(s) during period (see LR3.5.7G):
0
Equals:  
Balance under scheme(s) not yet issued/allotted at end of period:
275,420



Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000






 
 


BLOCK LISTING SIX MONTHLY RETURN

Information provided on this 
form
 must be typed or printed electronically 
and
 provided to an 
ris
.

Date:
 
11 May 2009

Name of 
applicant
:
GlaxoSmithKline plc
Name of scheme:
SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - Ordinary
Period of return:
From:
1 November 2008
To:
30 April 2009
Balance of unallotted securities under scheme(s) from previous return:
100,000
Plus:  
The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less:  
Number of 
securities
 issued/allotted under scheme(s) during period (see LR3.5.7G):
0
Equals:  
Balance under scheme(s) not yet issued/allotted at end of period:
100,000



Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000






 
 


BLOCK LISTING SIX MONTHLY RETURN

Information provided on this 
form
 must be typed or printed electronically 
and
 provided to an 
ris
.

Date:
 
11 May 2009

Name of 
applicant
:
GlaxoSmithKline plc
Name of scheme:
GlaxoSmithKline Savings Related Share Option Scheme
Period of return:
From:
1 November 2008
To:
30 April 2009
Balance of unallotted securities under scheme(s) from previous return:
6,
187,650
Plus:  
The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less:  
Number of 
securities
 issued/allotted under scheme(s) during period (see LR3.5.7G):
922,669
Equals:  
Balance under scheme(s) not yet issued/allotted at end of period:
5,264,981



Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000



SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: May 11, 2009

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc